Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (13)

2024

  1. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221

2021

  1. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors

    Cancers, Vol. 13, Núm. 15

2020

  1. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment

    Nature Immunology, Vol. 21, Núm. 2, pp. 120-134

  2. Monitoring abscopal responses to radiation in mice

    Methods in Enzymology (Academic Press Inc.), pp. 111-125

  3. PARP inhibitors in ovarian cancer

    New England Journal of Medicine

2019

  1. Apoptotic caspases cut down the immunogenicity of radiation

    OncoImmunology, Vol. 8, Núm. 11

  2. Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients

    OncoImmunology, Vol. 8, Núm. 11

2018

  1. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies

    Clinical Colorectal Cancer, Vol. 17, Núm. 4, pp. e617-e629

2017

  1. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    The Lancet Oncology, Vol. 18, Núm. 9, pp. 1159-1171

  2. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

    Gynecologic Oncology, Vol. 144, Núm. 1, pp. 65-71

2016

  1. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients

    European Journal of Cancer, Vol. 69, pp. 127-134

2014

  1. Gynecologic cancer intergroup (GCIG) consensus review for squamous cell carcinoma of the ovary

    International Journal of Gynecological Cancer, Vol. 24, Núm. 9, pp. S26-S29